Welcome to our dedicated page for Entasis Therapeutics Holdings news (Ticker: ETTX), a resource for investors and traders seeking the latest updates and insights on Entasis Therapeutics Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Entasis Therapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Entasis Therapeutics Holdings's position in the market.
Entasis Therapeutics has announced the selection of six abstracts for presentation, including three oral presentations, at IDWeek 2022, occurring from October 19-23, 2022, in Washington, D.C. These presentations focus on sulbactam-durlobactam (SUL-DUR) for treating infections caused by Acinetobacter baumannii. Highlights include efficacy studies comparing SUL-DUR to colistin, safety reviews from phase 3 trials, and pharmacokinetic analyses. This showcases the company's commitment to developing novel antibacterial therapies amid rising concerns over drug-resistant infections.
Innoviva, Inc. (Nasdaq: INVA) announced the expiration of its tender offer to acquire all shares of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) for $2.20 per share as of July 7, 2022. A total of 11,671,662 shares were validly tendered, meeting the minimum condition for the offer. The merger is expected to close on July 11, 2022, with Entasis becoming a wholly owned subsidiary of Innoviva. Shares not tendered will also be converted to cash at the same price. Post-merger, Entasis' common stock will no longer be traded on Nasdaq.
Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) presented multiple studies at the American Society for Microbiology's Microbe conference from June 9-13, 2022. Key focus areas included sulbactam-durlobactam (SUL-DUR) for multidrug-resistant Acinetobacter infections and ETX0462, a novel PBP inhibitor targeting Gram-negative bacteria. Oral and poster presentations detailed pharmacodynamics, in vitro activities, and the drug's efficacy against resistant strains, showcasing Entasis's commitment to addressing urgent antimicrobial resistance challenges.
Innoviva plans to acquire all outstanding shares of Entasis Therapeutics for $2.20 per share in cash, a 50% premium over Entasis’ last closing price of $1.47 on January 31, 2022. The total equity value for this acquisition is estimated at $113 million. Innoviva currently owns around 60% of Entasis shares, and the deal has received unanimous board approval from both companies. This acquisition aims to enhance Innoviva's diverse healthcare asset portfolio and leverage Entasis’ development of novel antibacterial therapies, including SUL-DUR, which targets multidrug-resistant infections.
Innoviva has announced plans to acquire all outstanding shares of Entasis for
Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) presented pivotal data from its Phase 3 ATTACK trial at the ATS 2022 conference. The study focused on the investigational drug Sulbactam-Durlobactam (SUL-DUR) for treating infections caused by Acinetobacter baumannii. Notable findings indicate a significant difference in mortality rates between SUL-DUR and colistin, with lower mortality observed in the SUL-DUR treatment group during critical treatment phases. This data is expected to attract interest from critical care physicians facing limited treatment options.
Innoviva reported a 5% increase in first-quarter royalties, totaling $93.5 million compared to Q1 2021. Notable earnings included $55.8 million from RELVAR®/BREO® ELLIPTA® and $29.3 million from TRELEGY® ELLIPTA®. However, income from operations saw a 2% decrease to $77.7 million due to the accounting consolidation of Entasis. Innoviva made a strategic investment of $45.0 million in Armata Pharmaceuticals and a $15.0 million offer to acquire Entasis, amidst a $9.4 million decline in asset fair values.
Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) reported a net loss of $15.3 million for Q1 2022, up from $10.7 million in Q1 2021. Research and development expenses increased to $11.0 million, driven by SUL-DUR initiatives. The SUL-DUR NDA is on track for submission in mid-2022, following successful presentations at the ECCMID conference. The company anticipates completion of the zoliflodacin Phase 3 trial enrollment in 2023. Cash reserves stood at $33.5 million, sufficient to fund operations through Q3 2022. Entasis continues to focus on developing treatments for drug-resistant infections.
Entasis Therapeutics (Nasdaq: ETTX) presented pivotal Phase 3 ATTACK trial results for sulbactam-durlobactam (SUL-DUR) at ECCMID 2022. The trial focused on patients with Acinetobacter baumannii infections, revealing that SUL-DUR showed a 19.0% all-cause mortality rate compared to 32.3% for colistin. Treatment-related adverse events were significantly lower with SUL-DUR at 12.1% versus 30.2% for colistin. Notably, the nephrotoxicity rate was 24.4% points lower with SUL-DUR (p=0.0002). Overall, these results suggest SUL-DUR may be a safer and more effective alternative to colistin.
Entasis Therapeutics Holdings (Nasdaq: ETTX) announced it will present multiple data on sulbactam-durlobactam (SUL-DUR) at the ECCMID conference, scheduled from April 23-26, 2022. Notably, the company will showcase topline results from its Phase 3 ATTACK trial evaluating SUL-DUR against colistin for treating infections caused by Acinetobacter. The trial is significant as it is the first to evaluate a drug targeting drug-resistant Gram-negative pathogens, demonstrating efficacy in all-cause mortality for carbapenem-resistant Acinetobacter, labeled an 'Urgent' threat by the CDC.
